Log in or Register for enhanced features | Forgotten Password?
White Papers | Suppliers | Events | Report Store | Companies | Dining Club | Medical Devices | Videos
Production & Manufacturing
Return to: PBR Home | Production & Manufacturing | OTC | News Listing

FDA approves Watson generic contraceptive pill

PBR Staff Writer Published 08 June 2011

The US Food and Drug Administration (FDA) has approved Watson Laboratories' Levonorgestrel and Ethinyl Estradiol Tablets, USP, 0.09mg/0.02mg.

Watson's Levonorgestrel and Ethinyl Estradiol Tablets, USP, 0.09mg/0.02mg are the generic version of Lybrel Tablets of Pfizer.

Lybrel is indicated for the prevention of pregnancy in women who choose to use oral contraceptives as a method of contraception.

Lybrel is a progesterone and estrogen combination birth control pill which works by preventing ovulation, thickening the mucus in the cervix and changing the lining of the uterus.